BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fretellier N, Idée J, Bruneval P, Guerret S, Daubiné F, Jestin G, Factor C, Poveda N, Dencausse A, Massicot F, Laprévote O, Mandet C, Bouzian N, Port M, Corot C. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br J Pharmacol 2012;165:1151-62. [PMID: 21740412 DOI: 10.1111/j.1476-5381.2011.01585.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Idée J, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Critical Reviews in Toxicology 2014;44:895-913. [DOI: 10.3109/10408444.2014.955568] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 9.4] [Reference Citation Analysis]
2 Robic C, Port M, Rousseaux O, Louguet S, Fretellier N, Catoen S, Factor C, Le Greneur S, Medina C, Bourrinet P, Raynal I, Idée JM, Corot C. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity. Invest Radiol 2019;54:475-84. [PMID: 30973459 DOI: 10.1097/RLI.0000000000000563] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 17.0] [Reference Citation Analysis]
3 Rowe PS, Zelenchuk LV, Laurence JS, Lee P, Brooks WM, McCarthy ET. Do ASARM peptides play a role in nephrogenic systemic fibrosis? Am J Physiol Renal Physiol 2015;309:F764-9. [PMID: 26336161 DOI: 10.1152/ajprenal.00201.2015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Giorgi H, Ammerman J, Briffaux J, Fretellier N, Corot C, Bourrinet P. Non-clinical safety assessment of gadoterate meglumine (Dotarem®) in neonatal and juvenile rats. Regulatory Toxicology and Pharmacology 2015;73:960-70. [DOI: 10.1016/j.yrtph.2015.09.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
5 Balassy C, Roberts D, Miller SF. Safety and efficacy of gadoteric acid in pediatric magnetic resonance imaging: overview of clinical trials and post-marketing studies. Pediatr Radiol 2015;45:1831-41. [PMID: 26045036 DOI: 10.1007/s00247-015-3394-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
6 Feng M, Fan YZ, Ma XJ, Li JX, Yang XG. The gadolinium-based contrast agent Omniscan® promotes in vitro fibroblast survival through in situ precipitation. Metallomics 2015;7:1103-10. [PMID: 25867453 DOI: 10.1039/c5mt00055f] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Kossmann S, Lagrange J, Jäckel S, Jurk K, Ehlken M, Schönfelder T, Weihert Y, Knorr M, Brandt M, Xia N, Li H, Daiber A, Oelze M, Reinhardt C, Lackner K, Gruber A, Monia B, Karbach SH, Walter U, Ruggeri ZM, Renné T, Ruf W, Münzel T, Wenzel P. Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension. Sci Transl Med 2017;9:eaah4923. [PMID: 28148841 DOI: 10.1126/scitranslmed.aah4923] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 16.3] [Reference Citation Analysis]
8 Chehabeddine L, Al Saleh T, Baalbaki M, Saleh E, Khoury SJ, Hannoun S. Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents. Critical Reviews in Toxicology 2019;49:262-79. [DOI: 10.1080/10408444.2019.1592109] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
9 Wáng YX, Schroeder J, Siegmund H, Idée JM, Fretellier N, Jestin-Mayer G, Factor C, Deng M, Kang W, Morcos SK. Total gadolinium tissue deposition and skin structural findings following the administration of structurally different gadolinium chelates in healthy and ovariectomized female rats. Quant Imaging Med Surg 2015;5:534-45. [PMID: 26435917 DOI: 10.3978/j.issn.2223-4292.2015.05.03] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
10 Fretellier N, Bouzian N, Parmentier N, Bruneval P, Jestin G, Factor C, Mandet C, Daubiné F, Massicot F, Laprévote O, Hollenbeck C, Port M, Idée J, Corot C. Nephrogenic Systemic Fibrosis-Like Effects of Magnetic Resonance Imaging Contrast Agents in Rats with Adenine-Induced Renal Failure. Toxicological Sciences 2013;131:259-70. [DOI: 10.1093/toxsci/kfs274] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
11 Fretellier N, Salhi M, Schroeder J, Siegmund H, Chevalier T, Bruneval P, Jestin-Mayer G, Delaloge F, Factor C, Mayer JF, Fabicki JM, Robic C, Bonnemain B, Idée JM, Corot C. Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation. Eur J Pharm Sci 2015;72:46-56. [PMID: 25736527 DOI: 10.1016/j.ejps.2015.02.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
12 Clases D, Sperling M, Karst U. Analysis of metal-based contrast agents in medicine and the environment. TrAC Trends in Analytical Chemistry 2018;104:135-47. [DOI: 10.1016/j.trac.2017.12.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
13 Fretellier N, Granottier A, Rasschaert M, Grindel AL, Baudimont F, Robert P, Idée JM, Corot C. Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?: A Comparative Gadoterate Versus Gadodiamide Study in Juvenile and Adult Rats. Invest Radiol 2019;54:61-71. [PMID: 30394964 DOI: 10.1097/RLI.0000000000000517] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
14 Rasschaert M, Emerit A, Fretellier N, Factor C, Robert P, Idée JM, Corot C. Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals: A Comparative Study of Macrocyclic Versus Linear Gadolinium Chelates in Renally Sensitized Rats. Invest Radiol 2018;53:328-37. [PMID: 29329151 DOI: 10.1097/RLI.0000000000000447] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
15 Swaminathan S, Bose C, Shah SV, Hall KA, Hiatt KM. Gadolinium contrast agent-induced CD163+ ferroportin+ osteogenic cells in nephrogenic systemic fibrosis. Am J Pathol 2013;183:796-807. [PMID: 23867799 DOI: 10.1016/j.ajpath.2013.06.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
16 Fretellier N, Maazouz M, Luseau A, Baudimont F, Jestin-mayer G, Bourgery S, Rasschaert M, Bruneval P, Factor C, Mecieb F, Idée J, Corot C. Safety profiles of gadolinium chelates in juvenile rats differ according to the risk of dissociation. Reproductive Toxicology 2014;50:171-9. [DOI: 10.1016/j.reprotox.2014.10.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
17 Fretellier N, Poteau N, Factor C, Mayer JF, Medina C, Port M, Idée JM, Corot C. Analytical interference in serum iron determination reveals iron versus gadolinium transmetallation with linear gadolinium-based contrast agents. Invest Radiol 2014;49:766-72. [PMID: 24943092 DOI: 10.1097/RLI.0000000000000081] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
18 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]